Shamburg News · 8-K filed Nov 12, 2026, 7:31 AM EST
Vor Biopharma Amends RemeGen License to Add RC298 Dual BAFF/APRIL Inhibitor
VOR · Vor Biopharma Inc.
- Material agreement
- Financing
- Reg FD disclosure
- Materiality: high
On November 11, 2026, Vor Biopharma entered into an amended and restated license agreement with RemeGen adding RC298, a dual-target fusion protein, to the exclusive ex-Greater China license for telitacicept. Vor Biopharma agreed to pay a $10 million upfront cash payment and issue a pre-funded warrant to purchase 2,300,000 shares of common stock at $0.0001 per share, with RemeGen eligible for up to $300 million in additional development milestones for the added products. The company also entered a securities purchase agreement and registration rights agreement with RemeGen, and the warrant closed on November 11, 2026.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 7.01, 9.01, accession 0001193125-26-456955.
Written from the filing by Shamburg Markets. Figures are as reported by the company.